AlloSure Lung dd-cfDNA Testing Service Receives Medicare Coverage
CareDx, Inc. has announced that its AlloSure Lung donor-derived cell-free DNA molecular testing service has received Medicare coverage.
Read MorePosted by Chris Wolski | Jul 12, 2023 | Molecular Diagnostic Analyzers |
CareDx, Inc. has announced that its AlloSure Lung donor-derived cell-free DNA molecular testing service has received Medicare coverage.
Read MorePosted by Chris Wolski | Jun 30, 2023 | Lung Cancer |
A blood-based test developed by researchers can predict the risk of dying from lung cancer when combined with a personalized risk model.
Read MorePosted by Melanie Hamilton-Basich | Jun 26, 2023 | Unknown Origin & Other Cancer Types |
By testing a range of therapies in organoids grown from the patient’s own tumor sample, SEngine’s PARIS Test identified off-label therapy that proved highly successful for one ovarian cancer patient.
Read MorePosted by Melanie Hamilton-Basich | Jun 23, 2023 | Lung Cancer |
Owlstone Medical announced new data on the development of a breath biopsy screening test for the early detection of lung cancer.
Read MorePosted by Chris Wolski | Jun 22, 2023 | Histology, Molecular Diagnostic Analyzers |
Orion combines histologic with molecular imaging information and offers deeper insight into a tumor’s type.
Read More